Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Weekly
Analytics
American chemical industry news
20 January 2026
Moderna and Merck Report 5-Year Data on Intismeran Autogene with KEYTRUDA
Intismeran autogene with KEYTRUDA shows 49% reduced risk of recurrence or death in high-risk melanoma over five years. Further data to be presented at a future medical conference.
19 January 2026
MOL Group to Acquire Majority Stake in Serbian NIS
MOL to gain control of Serbia's sole refinery, enhancing its Central and Southeastern European market presence. Transaction awaits regulatory approvals, aims for completion by March 2026.
19 January 2026
MOL Acquires Majority Stake in Serbian NIS
MOL to gain control of Serbia's sole refinery, enhancing its Central and Southeastern European market presence. Transaction awaits regulatory approvals, with completion aimed by March 2026.
19 January 2026
AGC Biologics Gains U.S. and EU Approval for Waskyra™ Gene Therapy
Waskyra™ gene therapy for Wiskott-Aldrich syndrome approved, offering a new treatment using patient cells, reducing donor dependency and rejection risk.
16 January 2026
Genmab Reports Phase 3 Trial Results for Epcoritamab in Relapsed/Refractory DLBCL
Epcoritamab shows improved progression-free survival in Phase 3 trial for R/R DLBCL. Safety profile consistent. Further analysis and regulatory discussions planned.
16 January 2026
Johnson & Johnson's CAPLYTA® Shows Promise for Remission in Major Depressive Disorder
CAPLYTA® nearly doubles remission rates in major depressive disorder when used with antidepressants, showing sustained benefits over six months in clinical studies.
How does the American chemical industry perform?
Find out with
chemXplore Analytics
Learn more
15 January 2026
RWE and Glenfarne Sign 20-Year LNG Supply Deal
RWE to receive 1 MTPA of LNG from Texas LNG, starting 2030. The facility will use low-emission tech and ensure GHG monitoring. This is RWE's second long-term U.S. LNG contract.
15 January 2026
Covestro Named Top Employer in China for Eight Years
Covestro's HR practices excel in work environment, diversity, and digital HR, earning recognition from the Top Employers Institute for the eighth year.
15 January 2026
Arkema Earns Top Employer 2026 in 10 Countries
Recognized for HR excellence, Arkema excels in quality of life, diversity, skills development, and digital HR, covering 82% of its workforce across 10 countries.
15 January 2026
Iberdrola Achieves Top Employer Enterprise Seal Again
Recognized for excellence in people management, Iberdrola surpasses industry standards, securing the Top Employer Enterprise seal for the second year, with certifications in ten countries.
14 January 2026
Johnson & Johnson's TECVAYLI® Shows Improved Survival in Multiple Myeloma Patients
TECVAYLI® monotherapy reduces disease progression and death risk in multiple myeloma patients refractory to anti-CD38 and lenalidomide, showing superior survival benefits.
14 January 2026
dsm-firmenich Names Nikeisha van Sleeuwen as CHRO
Nikeisha van Sleeuwen becomes CHRO on April 1, 2026, succeeding Mieke Van de Capelle, who retires after a decade of service.
13 January 2026
Boehringer Ingelheim Advances IL-11 Inhibitor to Phase II for IPF
BI 765423, targeting IL-11, enters Phase IIa trials for IPF, aiming to improve lung function. Pre-clinical studies show promise in halting fibrosis and restoring lung functionality.
13 January 2026
BASF Acquires AgBiTech for Biological Insect Control
BASF to fully acquire AgBiTech by 2026, enhancing insect control solutions in Brazil with NPV technology, supporting sustainable agriculture and integrated pest management.
12 January 2026
NVIDIA and Lilly Launch AI Lab for Drug Discovery
The lab will invest $1B in AI to enhance drug discovery, integrating robotics and AI for continuous learning and improved medicine production.
12 January 2026
Boehringer Ingelheim and Jazz Pharmaceuticals Collaborate on HER2-Targeted Breast Cancer Therapy
Phase 1b study to test zongertinib and zanidatamab combo in HER2-positive breast cancer, aiming to improve outcomes with dual HER2-targeted therapy.
9 January 2026
Yara's 2026 Strategy: Resilient Earnings and Sustainable Growth
Yara aims for $600M cash flow growth by 2030, focusing on asset optimization, low-emission ammonia, and shareholder returns, while maintaining strict capital discipline.
9 January 2026
Kemira Acquires AquaBlue
The acquisition boosts Kemira's North American presence in industrial water treatment, integrating AquaBlue's expertise with Kemira's technologies.
8 January 2026
Johnson & Johnson Partners with U.S. Government to Enhance Medicine Access and Reduce Costs
Agreement with U.S. government to lower drug costs. $55B investment in U.S. manufacturing, including new facilities in Pennsylvania and North Carolina, creating thousands of jobs.
8 January 2026
Lilly's Taltz and Zepbound Show Superior Results in Psoriatic Arthritis and Obesity Trial
The trial showed Taltz and Zepbound together improved psoriatic arthritis and weight loss more than Taltz alone, with mild to moderate side effects.
8 January 2026
Takeda and Halozyme Collaborate on Vedolizumab
The partnership aims to enhance vedolizumab delivery for IBD treatment, improving patient care and expanding access with ENHANZE technology.
8 January 2026
SABIC Divests European Petrochemicals and Americas/Europe Engineering Thermoplastics for $950 Million
The divestments aim to optimize the portfolio, enhance cash flow, and focus on high-margin markets, while maintaining strategic access and customer service.
7 January 2026
Borouge Implements AI Operations at Ruwais for Enhanced Efficiency
AI operations at Ruwais boost efficiency by 20%, cut downtime by 20%, and reduce costs by 15%, enhancing safety and sustainability. Part of a $575M value generation program.
7 January 2026
Veolia Issues €2.5 Billion in Bonds
Veolia's bond issuance attracted 570+ orders, peaking at €10.5B. Strong demand led to favorable terms, highlighting investor confidence in Veolia's growth and financial stability.
7 January 2026
Lilly Acquires Ventyx Biosciences to Enhance Inflammatory Disease Therapies
Ventyx's small molecule pipeline targets chronic inflammation in cardiometabolic, neurodegenerative, and inflammatory diseases, aiming for improved efficacy and safety.
7 January 2026
Topsoe Announces CEO Transition: Scaltritti to Succeed Baan
Baan steps down as CEO in 2026. Scaltritti, current CCO, will succeed him. Baan led significant transformations, including green hydrogen and sustainable fuel initiatives.
7 January 2026
Corteva and bp Form Etlas Biofuel Feedstock Venture
Etlas will produce biofuel feedstocks from crops, aiming for 1M tonnes annually by mid-2030s, supporting SAF and RD demand growth without extra land use.
7 January 2026
Merck Finalizes Cidara Therapeutics Acquisition
Merck acquires Cidara, enhancing its respiratory portfolio with CD388, a long-acting antiviral for influenza prevention, impacting 2026 R&D expenses and EPS.
7 January 2026
Sunrise Wind Challenges Lease Suspension in Court
Sunrise Wind seeks a preliminary injunction against a lease suspension, citing legal violations and project delays, impacting energy supply and jobs.
6 January 2026
Johnson & Johnson Reports Positive Phase 2 Results for Nipocalimab in SLE Study
Nipocalimab shows promise in reducing SLE activity, meeting primary and secondary endpoints in Phase 2b JASMINE study, with a consistent safety profile. Phase 3 program initiated.
Next →
